Extremely significant positive changes in fundamentals have recently occurred for Corcept Therapeutics Inc (NASDAQ: CORT): the consensus estimate for December, 2024 increased significantly, the stock’s power rating rose above 70, the consensus estimate for December, 2025 increased significantly, and significant quarterly earnings acceleration occurred.
In light of these very positive signals we are reviewing our current Overall Rating of C. We would view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
CORT is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.
Corcept Therapeutics has a current Value Trend Rating of C (Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Corcept Therapeutics has a poor Appreciation Score of 20 but a good Power Rating of 75, leading to the Neutral Value Trend Rating.
Recent Price Action
Corcept Therapeutics Inc (NASDAQ: CORT) stock closed at $34.51 on 8/5/24 after a decline of -2.2%. However, below average trading volume at 80% of normal accompanied the decline. The stock has declined -3.1% during the last week but has been strong relative to the market over the last nine months.
Be the first to comment